BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 12:24:00 PM | Browse: 1618 | Download: 2406
 |
Received |
|
2014-01-11 14:42 |
|
Peer-Review Started |
|
2014-01-11 17:15 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2014-02-09 21:21 |
|
Revised |
|
2014-02-28 01:53 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2014-06-20 11:55 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2014-06-20 12:08 |
|
Articles in Press |
|
2014-06-20 13:20 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2014-08-11 08:39 |
|
Publish the Manuscript Online |
|
2014-08-20 20:37 |
| Category |
Rheumatology |
| Manuscript Type |
Topic Highlights |
| Article Title |
Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Charles J Malemud and David E Blumenthal |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Genentech/Roche Group and the Case Western Reserve University School of Medicine Visual Sciences Research Core |
P30 EY-011373 |
|
| Corresponding Author |
Charles J Malemud, PhD, Department of Medicine, Division of Rheumatic Diseases, The Arthritis Research Laboratory, Foley Medical Building, 2061 Cornell Road, Cleveland, OH 44106-5076,
United States. cjm4@cwru.edu
|
| Key Words |
Clinical trials; Protein kinase; Signal transduction; Small molecule inhibitor; Rheumatoid arthritis |
| Core Tip |
Signal transduction is a regulator of gene expression in cells. Janus kinase/Signal Transducers and Activators of Transcription (JAK/STAT) signaling is activated by pro-inflammatory cytokines which contributes to immune-mediated inflammation in rheumatoid arthritis. Medicinal chemistry was employed to develop JAK small molecule inhibitors for determining their clinical efficacy in active rheumatoid arthritis patients. Tofacitinib, a JAK small molecule inhibitor, is now generally used to treat moderate to severe rheumatoid arthritis patients who have not adequately responded to disease-modifying anti-rheumatic drugs or various biologic agents. The clinical efficacy of JAK small molecule inhibitors provides the impetus for future drug discovery targeted at other signal transduction pathways in rheumatoid arthritis. |
| Publish Date |
2014-08-20 20:37 |
| Citation |
Malemud CJ, Blumenthal DE. Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives. World J Orthop 2014; 5(4): 496-503 |
| URL |
http://www.wjgnet.com/2218-5836/full/v5/i4/496.htm |
| DOI |
http://dx.doi.org/10.5312/wjo.v5.i4.496 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
